Technical Data
| Formula | C62H86N12O16 |
||||||||||
| Molecular Weight | 1255.42 | CAS No. | 50-76-0 | ||||||||
| Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (79.65 mM) | ||||||||
| Water | Insoluble | ||||||||||
| Ethanol | Insoluble | ||||||||||
| In Vivo (Add solvents to the product individually and in order.) |
|
||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||||||
Preparing Stock Solutions
Biological Activity
| Description | Actinomycin D (Dactinomycin, Act D, RASP-101) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. Actinomycin D (Dactinomycin) inhibits DNA repair and rests the cell cycle at G1 phase with IC50 of 0.42 μM and 0.4 nM, respectively. Actinomycin D is an RNA and protein synthesis inhibitor that can suppress bacterial protein synthesis. Actinomycin D is an autophagy activator, induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukaemia.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
||||||
| In vitro | Actinomycin D (Dactinomycin) markedly reduces SMC proliferation via the inhibition of BrdU incorporation at 80 nM. This is further supported by the G1-phase arrest using a flowcytometric analysis. The protein expression levels of proliferating cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and Raf are all suppressed by this compound. Extracellular signalregulated kinases (Erk) involved in cell-cycle arrest are found to be increased by it. |
||||||
| In Vivo | Actinomycin D (Dactinomycin) targets survival proteins TOSO, BCL2 and MCL1 and is active in two different mouse models that are characterised by either unmutated B-cell receptor or inactive p53 function, both of which are known negative prognostic factors in CLL. |
Protocol (from reference)
| Cell Assay: |
|
|---|---|
| Animal Study: |
|
References
|
Sellecks Actinomycin D (Dactinomycin) Has Been Cited by 151 Publications
| Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression [ Signal Transduct Target Ther, 2025, 10(1):236] | PubMed: 40681503 |
| Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer [ Mol Cancer, 2025, 24(1):217] | PubMed: 40819058 |
| RNA m6A regulates the transcription and heterochromatin state of retrotransposons in Arabidopsis [ Nat Plants, 2025, 11(11):2300-2318] | PubMed: 41136675 |
| DCAF13-mediated K63-linked ubiquitination of RNA polymerase I promotes uncontrolled proliferation in Breast Cancer [ Nat Commun, 2025, 16(1):557] | PubMed: 39788980 |
| Microprotein PLUM encoded by Lin28b uORF is a cytoplasmic determinant of pluripotency and embryonic development [ Nat Commun, 2025, 16(1):10324] | PubMed: 41298451 |
| 8q24 derived ZNF252P promotes tumorigenesis by driving phase separation to activate c-Myc mediated feedback loop [ Nat Commun, 2025, 16(1):1986] | PubMed: 40011431 |
| Ubiquitination-Dependent LLGL2 Degradation Drives Colorectal Cancer Progression via THBS3 mRNA Stabilization [ Adv Sci (Weinh), 2025, 12(39):e01656] | PubMed: 40619612 |
| IGF2BP3-mediated m6A modification of RASGRF1 promoting joint injury in rheumatoid arthritis [ Bone Res, 2025, 13(1):51] | PubMed: 40355406 |
| Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification [ Mol Ther, 2025, S1525-0016(25)00716-6] | PubMed: 40914805 |
| PCBP2-dependent secretion of miRNAs via extracellular vesicles contributes to the EGFR-driven angiogenesis [ Theranostics, 2025, 15(4):1255-1271] | PubMed: 39816681 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.